Abstract
Although rest tremor is the typical form of tremor associated with Parkinson's disease (PD), particularly the tremor‐dominant subtype,1 parkinsonian patients may also exhibit postural tremor. In many parkinsonian patients, this postural tremor emerges after a latency of a few seconds or even minutes. In our original description, we coined the term “re‐emergent tremor” to differentiate this postural tremor from essential tremor, which occurs without any latency, and to link it to PD rest tremor that is “reset” after some latency when a new holding posture is assumed.2 The relationship of this re‐emergent tremor to the typical rest tremor is supported by the observation that this tremor shares many characteristics with the typical rest tremor, such as the same, 3 to 5‐Hz frequency, occasional supinating‐pronating component, and relatively good response to dopaminergic therapy. Rarely, postural tremor, occurring after a brief (2–4 seconds) latency can be seen even without observable rest tremor.3 In most patients with PD, it is the postural (re‐emergent) tremor that is more troublesome for them than the typical rest tremor, because this re‐emergent tremor interferes with their ability to hold objects, such as newspapers, against gravity and results in spilling of liquids. Postural tremor of PD is often misdiagnosed as essential tremor, and this diagnostic challenge can be further confounded when both conditions coexist.4 When that occurs, the postural tremor is present without latency, although the amplitude may gradually increase as the underlying re‐emergent tremor becomes more evident.
Disclosures
Funding Sources and Conflicts of Interest: Dr. Jankovic has received research grants from Adamas Pharmaceuticals, Inc.; Allergan, Inc.; Auspex Pharmaceuticals, Inc.; CHDI Foundation; Civitas/Acorda Therapeutics; Huntington Study Group; Ipsen Limited; Kyowa Haako Kirin Pharma, Inc.; Lundbeck Inc.; Medtronic; Merz Pharmaceuticals; Michael J. Fox Foundation for Parkinson Research; National Institutes of Health; National Parkinson Foundation; Omeros Corporation; Parkinson Study Group; Pfizer; Prothena Biosciences Inc.; Psyadon Pharmaceuticals, Inc.; St. Jude Medical; and Teva Pharmaceutical Industries Ltd. He has served as a consultant or as an advisory committee member for: Adamas Pharmaceuticals, Inc.; Allergan, Inc.; Auspex Pharmaceuticals, Inc.; and Teva Pharmaceutical Industries Ltd. He has received royalties from Cambridge, Elsevier, Future Science Group, Hodder Arnold, Lippincott Williams and Wilkins, and Wiley‐Blackwell. In addition, he serves on the editorial boards of Medlink, Neurology, Expert Review of Neurotherapeutics, Neurology in Clinical Practice, The Botulinum Journal, PeerJ, Therapeutic Advances in Neurological Disorders, Neurotherapeutics, Tremor and Other Hyperkinetic Movements, Journal of Parkinson's Disease, and UpToDate.
Financial Disclosures for the previous 12 months: The author reports no other sources of funding and no other conflicts of interest.
Supporting information
Supporting information may be found in the online version of this article.
Relevant disclosures and conflicts of interest are listed at the end of this article.
References
- 1. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014;71:499–504. [DOI] [PubMed] [Google Scholar]
- 2. Jankovic J, Schwartz KS, Ondo W. Re‐emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:646–650. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Louis ED, Pullman SL, Eidelberg D, Dhawan V. Re‐emergent tremor without accompanying rest tremor in Parkinson's disease. Can J Neurol Sci 2008;35:513–515. [DOI] [PubMed] [Google Scholar]
- 4. Thenganatt MA, Jankovic J. The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord 2016;22(suppl 1):S162–S165. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.